Arndt Vogel: Lenvatinib Plus Pembrolizumab vs SOC in Previously Treated mCRC
Arndt Vogel shared a post on X:
“Lenvatinib Plus Pembrolizumab vs SOC in Previously Treated mCRC
Final results of phs-3 LEAP-017, 480 pts
mOS 9.8 vs 9.3 mo
TRAE≥3 58 vs 42.1%
no improvement, no benefit compared to SOC…”
Read further
Source: Arndt Vogel/X
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.